- Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trialsSujata Patil
Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Urol 188:2095-100. 2012..We assessed temporal shifts in the frequency of risk factors for patients with metastatic renal cell carcinoma in a multicenter, international data set...
- Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-αS Patil
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Br J Cancer 106:1587-90. 2012..We assessed between-treatment differences in overall benefit using a quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (TWiST; Gelber and Goldhirsch) analysis...
- Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinomaS Patil
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Ann Oncol 22:295-300. 2011....